Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
DXV3WD
|
||||
| Drug Name |
D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-Pro(4-O-methyl)-pro(2,3-dibenzo)-arg
|
||||
| Synonyms |
CHEMBL2370158
|
||||
| Indication | Discovery agent | Investigative | [1587926] | ||
| Formula |
C55H83N19O14S
|
||||
| Canonical SMILES |
CO[C@H]1C[C@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H]2C[C@H](O)CN2C(=O)[C@@H]3CCCN3C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](N)CCCN=C(N)N)c4cccs4)C(=O)N5Cc6ccccc6C[C@H]5C(=O)N[C@@H](CCCN=C(N)N)C(=O)O
|
||||
| InChI |
InChI=1S/C55H83N19O14S/c1-88-32-23-40(51(85)72-25-30-10-3-2-9-29(30)21-38(72)46(80)68-35(52(86)87)13-6-18-65-55(61)62)74(27-32)49(83)36(28-75)69-47(81)43(41-15-8-20-89-41)70-42(77)24-66-45(79)39-22-31(76)26-73(39)50(84)37-14-7-19-71(37)48(82)34(12-5-17-64-54(59)60)67-44(78)33(56)11-4-16-63-53(57)58/h2-3,8-10,15,20,31-40,43,75-76H,4-7,11-14,16-19,21-28,56H2,1H3,(H,66,79)(H,67,78)(H,68,80)(H,69,81)(H,70,77)(H,86,87)(H4,57,58,63)(H4,59,60,64)(H4,61,62,65)/t31-,32-,33+,34-,35-,36-,37-,38-,39-,40-,43-/m0/s1
|
||||
| InChIKey |
WRPSCMJWFRBZKH-HWDJTILLSA-N
|
||||
| Target and Pathway | |||||
| Target(s) | B1 bradykinin receptor | Target Info | [1587926] | ||
| B2 bradykinin receptor | Target Info | [1587926] | |||
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Complement and coagulation cascades | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| Regulation of actin cytoskeleton | |||||
| Pathways in cancerhsa04020:Calcium signaling pathway | |||||
| cGMP-PKG signaling pathway | |||||
| Sphingolipid signaling pathway | |||||
| Endocrine and other factor-regulated calcium reabsorption | |||||
| Chagas disease (American trypanosomiasis) | |||||
| Pathways in cancer | |||||
| Pathway Interaction Database | Direct p53 effectors | ||||
| Validated transcriptional targets of deltaNp63 isoforms | |||||
| WikiPathways | Complement and Coagulation Cascades | ||||
| ACE Inhibitor Pathway | |||||
| Regulation of Actin Cytoskeleton | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Vitamin D Receptor Pathway | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP554:ACE Inhibitor Pathway | |||||
| Nifedipine Activity | |||||
| GPCR downstream signaling | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.